Celldex Therapeutics Stock News

CDX-0159 had good early-stage trial results for hives. CDX-1140 for cancer has some early encouraging data. CDX-527 bispecific cancer therapy is in a Phase 1 trial.

Investors need to pay close attention to Celldex (CLDX) stock based on the movements in the options market lately.

Investors need to pay close attention to Celldex (CLDX) stock based on the movements in the options market lately.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) SVP Sarah Cavanaugh sold 7,323 shares of Celldex Therapeutics stock in a transaction dated Wednesday, December 8th. The stock was sold at an average price of $40.00, for a total transaction of $292,920.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. []

Celldex Therapeutics, Inc. (NASDAQ:CLDX) VP Elizabeth Crowley sold 4,000 shares of the companys stock in a transaction on Wednesday, December 8th. The stock was sold at an average price of $40.00, for a total value of $160,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Celldex Therapeutics []

Brokerages expect Celldex Therapeutics, Inc. (NASDAQ:CLDX) to announce $1.39 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Celldex Therapeutics earnings, with estimates ranging from $200,000.00 to $3.48 million. Celldex Therapeutics reported sales of $3.79 million in the same quarter last year, which indicates a []

Nisa Investment Advisors LLC bought a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 2,800 shares of the biopharmaceutical companys stock, valued at approximately $151,000. A number of other institutional investors have also recently modified their holdings []

HAMPTON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-0159 for the treatment of pr

HAMPTON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-0159 for the treatment of prurigo nodularis (PN). CDX-0159 is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. PN is a chronic skin disease that causes hard, intensely itchy lumps/nodules to form on the skin. The itching (pruritus) can be intense, causing people to scratch themselves to the point of bleeding or pain, which can form lesions and perpetuate the disease cycle.

Wall Street analysts expect Celldex Therapeutics, Inc. (NASDAQ:CLDX) to report ($0.42) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Celldex Therapeutics earnings, with the lowest EPS estimate coming in at ($0.47) and the highest estimate coming in at ($0.38). Celldex Therapeutics reported earnings of ($0.26) []

During the last session, Celldex Therapeutics Inc. (NASDAQ:CLDX)s traded shares were 0.46 million, with the beta value of the company hitting 2.72. At the end of the trading day, the stocks price was $41.12, reflecting an intraday gain of 0.61% or $0.25. The 52-week high for the CLDX share is $57.20, that puts it down The Celldex Therapeutics Inc. (NASDAQ: CLDX) Stock Jumped -10.26% In A Single Month Are There Any Hopes For A Gain? Read More »

Metropolitan Life Insurance Co NY acquired a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,107 shares of the biopharmaceutical companys stock, valued at approximately $371,000. Several other hedge funds also recently bought and sold []

Celldex Therapeutics, Inc. (NASDAQ:CLDX) was the recipient of a significant increase in short interest in October. As of October 29th, there was short interest totalling 3,720,000 shares, an increase of 25.7% from the October 14th total of 2,960,000 shares. Based on an average daily volume of 472,500 shares, the short-interest ratio is presently 7.9 days. []

Equities analysts expect Celldex Therapeutics, Inc. (NASDAQ:CLDX) to report ($0.42) earnings per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Celldex Therapeutics earnings. The highest EPS estimate is ($0.38) and the lowest is ($0.47). Celldex Therapeutics reported earnings of ($0.26) per share in the same quarter last year, []

Nuveen Asset Management LLC bought a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the 2nd quarter, Holdings Channel reports. The institutional investor bought 142,031 shares of the biopharmaceutical companys stock, valued at approximately $4,750,000. Other hedge funds have also recently made changes to their positions in the company. BNP Paribas Arbitrage SA raised its []